No new data or financial impact in this abstract-only announcement. Monitor EAACI presentations on June 14 for any substantive efficacy or safety readouts from the Phase 1 CDX-622 data or barzolvolimab long-term results; near-term price reaction likely muted unless unexpected positive/negative signals emerge.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $29.96entry
- T+1 · 5mo ago +4.37%α +3.83% · $31.27
- T+5 · 5mo ago +9.91%α +9.48% · $32.93
- T+20 · 4mo ago +30.11%α +28.22% · $38.98
- T+60 · 2mo ago +30.57%α +26.75% · $39.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold urticaria, plus a late-breaking poster on first-in-human Phase 1 results for CDX-622, a bispecific targeting TSLP and mast cells. This is a routine scientific conference update with no new efficacy or safety data disclosed, providing no material stock-moving catalyst.
Key Facts
- Three presentations to be given at EAACI Annual Congress, June 12-15, 2026, in Istanbul, Türkiye
- Two flash talks on barzolvolimab: one on long-term off-treatment angioedema improvement in CSU, another on psychometric validation of WI-NRS in cold urticaria
- Late-breaking poster on Phase 1 first-in-human results of CDX-622 (bispecific targeting TSLP and mast cells via SCF) in healthy volunteers
- Barzolvolimab is in Phase 3 studies for CSU and ColdU/SD, and Phase 2 studies for prurigo nodularis and atopic dermatitis
Financial Impact
No financial data disclosed; pipeline milestone update with no dollar amounts or revenue impact
Risk Factors
- Barzolvolimab Phase 3 results may fail to replicate Phase 2 efficacy or safety
- CDX-622 is early-stage (Phase 1); no guarantee of clinical benefit or regulatory path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310079 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers